e8vk
 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934

     
Date of Report (Date of earliest event reported):   September 4, 2002

United Therapeutics Corporation

(Exact Name of Registrant as Specified in Charter)
         
Delaware   000-26301   52-1984749

 
 
(State or Other
Jurisdiction of
Incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification Number)
     
1110 Spring Street    
Silver Spring, MD   20910

 
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code:

(301) 608-9292

 


 

Item 5. Other Events.

         On September 4, 2002, United Therapeutics Corporation (the “Company”) issued a press release announcing the appointment of the Hon. Louis W. Sullivan to the Company’s board of directors. A copy of the press release is attached hereto and incorporated herein by this reference.

Item 7. Exhibits

         (c)  Exhibits

     
Exhibit No.   Description of Exhibit

 
99.1   Press release dated September 4, 2002.

 


 

SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

             
        UNITED THERAPEUTICS CORPORATION
             
Dated:   September 4, 2002   By:   /s/ Paul A. Mahon
           
        Name:   Paul A. Mahon
        Title:   Senior V.P. and General Counsel

 


 

EXHIBIT INDEX

     
Exhibit No.   Description of Exhibit

 
99.1   Press release dated September 4, 2002